Skip to main content
TipRanks
Go Ultimate75% OFF

Arcutis Biotherapeutics (ARQT) AI Stock Analysis

993 Followers
ARQT

Arcutis Biotherapeutics

(NASDAQ:ARQT)

Select Model
Rating:75Outperform
Price Target:$38.00â–²(37.63% Upside)
Action:reiterated
Date:11/05/26

ARQT scores well primarily on improved financial performance (return to profitability, strong cash generation, and low current leverage) and a strongly positive earnings update with raised 2026 revenue guidance and sustained demand momentum. The score is held back by expensive valuation (very high P/E) and technical indicators suggesting the stock is extended/overbought after a strong uptrend.

Positive Factors
ZORYVE demand growthRapid revenue and prescription growth indicates expanding adoption of ZORYVE across its dermatology markets. Continued demand momentum, broad growth across indications, and strong prescriber acceptance can support a durable commercial franchise over the next several quarters.
Negative Factors
Profitability turnaround remains recentAlthough profitability has improved, the thin current net margin and history of substantial losses make the turnaround less proven than the revenue growth suggests. A slowdown in demand or continued investment could quickly reduce earnings and weaken confidence in sustainable cash generation.

Arcutis Biotherapeutics (ARQT) vs. SPDR S&P 500 ETF (SPY)

-40%-30%-20%-10%0%10%20%30%ARQT-6.38%SPY+13.11%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$3.49B
Dividend Yield
―
Average Volume (3M)
2.62M
Price to Earnings (P/E)
118.7
Beta (1Y)
0.59
Revenue Growth
60.00%
EPS Growth
―
Country
US
Employees
354
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Arcutis Biotherapeutics Business Overview & Revenue Model

Company Description

Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has...

Arcutis Biotherapeutics Earnings Call Summary

Earnings Call Date:Nov 04, 2026(Q3-2026)|% Change Since:-18.91%|Next Earnings Date:Mar 02, 2027
Earnings Call SentimentPositive

The call was strongly positive, with robust demand and revenue growth, record quarterly prescriptions, raised 2026 revenue guidance, positive net income and operating cash flow, and progress across commercial, clinical and pipeline initiatives. The main negatives were higher operating expenses, gross-to-net remaining in the low 50s, the timing of expected operating leverage, and the preliminary nature of several pipeline opportunities. Highlights significantly outweighed the lowlights.

Positive Updates

Strong Third-Quarter Revenue Growth
Net product revenues were $143.9 million in the third quarter of 2026, up 45% from the third quarter of 2025 and up 11% versus the second quarter of 2026. Growth was driven primarily by increased patient demand and very modest improvements in gross-to-net sales deductions.

Negative Updates

Gross-to-Net Rate Remains in the Low 50s
Gross-to-net improved only marginally from the second quarter, primarily because of lower co-pay expense, and remained stable in the low 50s. Management expects gross-to-net discounts to remain stable in the fourth quarter, with minimal pricing-driven sales growth.

Company Guidance

Management increased full-year 2026 net revenue guidance to between $535 million and $545 million from the previous range of $525 million to $540 million; for the fourth quarter, it expects substantial sequential demand growth, typical fourth quarter seasonality tailwinds, gross to net discounts to remain stable, minimal pricing-driven sales growth, and expenses to remain at this level, while expecting to maintain positive cash flow through the end of the year. Management expects demand impact from the Skin to Believe In campaign to start being more visible in early 2027, expects the grant rate by dermatology clinicians to remain above 90%, and expects to improve growth and inflect 2027 net sales, with the dramatic shift in operational leverage coming in the latter part of '27 into '28; it also expects a vitiligo readout in the fourth quarter, an HS readout in the first quarter of 2027, and a PDUFA action date on February 23, 2027, for ZORYVE cream 0.05% in infants down to 3 months.

Arcutis Biotherapeutics Financial Statement Overview

Summary

Financials reflect a meaningful turnaround: TTM revenue rose to about $509M with very high gross margins (~90%+) and a shift to positive operating profit, net income (~$30M), and positive free cash flow (~$60M). Balance sheet leverage is low (debt-to-equity ~0.05) with improving equity and positive ROE. The key risk is durability, as losses and negative cash flow were common in recent years and current net margin remains relatively thin (~5.9%).

Income Statement

74Positive

Balance Sheet

82Very Positive

Cash Flow

79Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue508.68M376.07M196.54M59.61M3.69M0
Gross Profit463.81M339.38M177.41M54.62M2.93M-763.00K
EBITDA44.82M1.78M-109.63M-228.56M-294.87M-205.90M
Net Income29.91M-16.14M-140.04M-262.14M-311.46M-206.36M
Balance Sheet
Total Assets524.43M432.97M348.89M341.37M449.27M408.15M
Cash, Cash Equivalents and Short-Term Investments259.46M220.98M227.96M271.86M409.59M388.60M
Total Debt114.62M6.27M110.58M205.92M202.54M77.56M
Total Liabilities280.46M243.49M191.35M252.70M239.69M110.47M
Stockholders Equity243.97M189.48M157.54M88.67M209.58M297.68M
Cash Flow
Free Cash Flow59.71M-6.31M-112.30M-247.49M-281.00M-175.62M
Operating Cash Flow59.96M-5.63M-112.16M-247.06M-257.71M-174.63M
Investing Cash Flow-82.82M-30.25M28.82M180.23M-87.20M-75.95M
Financing Cash Flow9.23M6.97M66.20M101.32M301.80M281.95M

Arcutis Biotherapeutics Technical Analysis

Technical Analysis SentimentNeutral
Last Price27.61

Price Trends

50DMA27.74Negative
100DMA27.00Positive
200DMA25.40Positive

Market Momentum

MACD-0.32Positive
RSI46.65Neutral
STOCH44.50Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ARQT, the sentiment is Neutral. The current price of 27.61 is below the 20-day moving average (MA) of 29.60, below the 50-day MA of 27.74, and above the 200-day MA of 25.40, indicating a neutral trend. The MACD of -0.32 indicates Positive momentum. The RSI at 46.65 is Neutral, neither overbought nor oversold. The STOCH value of 44.50 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ARQT.

Arcutis Biotherapeutics Risk Analysis

Arcutis Biotherapeutics disclosed 72 risk factors in its most recent earnings report. Arcutis Biotherapeutics reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

3 New Risks
1.We are a large accelerated filer and no longer qualify as a "smaller reporting company," which requires additional compliance initiatives and heightened disclosure and reporting requirements.Q4, 2024
2.We could be subject to additional tax liabilitiesQ4, 2024
3.We expect to be a large accelerated filer and will no longer qualify as a "smaller reporting company" which will require additional compliance initiatives and heightened disclosure and reporting requirements.Q3, 2024

Arcutis Biotherapeutics Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

ARQT against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
ARQTARQT75Outperform$3.46B118.6514.18%―60.00%―
PVLAPVLA64Neutral$2.14B-26.65-44.44%―――
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
MANEMANE50Neutral$5.27B-47.30-19.90%――-57.61%
ACRSACRS48Neutral$555.14M-6.03-59.20%―-59.34%57.30%
MLTXMLTX39Underperform$918.30M-2.93-79.95%――-10.20%
ALMSALMS30Underperform$570.56M-1.27-99.61%―-67.28%9.70%

* Healthcare Sector Average

Performance Comparison

0%100%200%300%ARQTPVLAACRSMLTXALMSMANEDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
ARQT and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
ARQTArcutis Biotherapeutics Inc27.610.281.02%
PVLAPalvella Therapeutics, Inc.146.5855.0460.13%
ACRSAclaris Therapeutics Inc.3.501.0945.23%
MLTXMoonlake Immunotherapeutics10.79-2.21-17.00%
ALMSAlumis Inc.4.39-2.53-36.49%
MANEVeradermics, Incorporated124.8687.11230.75%

Arcutis Biotherapeutics Corporate Events

Business Operations and StrategyExecutive/Board Changes

Arcutis Biotherapeutics Adds Veteran Leader to Board

Positive
Oct 28, 2026

On October 23, 2026, Arcutis Biotherapeutics increased the size of its board of directors from ten to eleven members and appointed veteran pharmaceutical executive Dr. Robert Scott as an independent Class II director, with his term running through th...

Business Operations and StrategyExecutive/Board ChangesFinancial Disclosures

Arcutis Biotherapeutics Announces Key Commercial Leadership Changes

Positive
Aug 5, 2026

Arcutis Biotherapeutics reported strong second-quarter 2026 results, underscoring the momentum of its ZORYVE franchise in immuno-dermatology. Net product revenues climbed to $129.9 million, up 59% year over year and 23% sequentially, supported by ris...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 05, 2026